Health Care • Biotechnology: Pharmaceutical Preparations
$21.07 ▼ -0.41
(-1.91%)
MKT CAP: $1.48B • VOL: 625.8K
52W L $13 52W H $41
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
TYRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$132.8M | -$104.2M | -$79.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$119.9M | -$86.5M | -$69.1M |
| EBITDA (Normalized) | -$132.6M | -$103.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$95.1M | -$69.8M | -$50.1M |
| Capital Expenditures (CapEx) | $141.0K | $664.0K | — |
| Free Cash Flow (FCF) | -$95.3M | -$70.4M | -$50.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -32.8% | — |
| Cash & Short-Term Equivalents | $77.4M | $92.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $259.2M | $343.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TYRA.